%PDF-1.4
%
62 0 obj
<>
endobj
59 0 obj
<>
endobj
114 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2005-08-05T16:27:55Z
2024-03-28T07:31:20-07:00
QuarkXPressª: AdobePS 8.6 (219)
2024-03-28T07:31:20-07:00
application/pdf
Heather
2004-743.aug
uuid:36c0345b-1dd2-11b2-0a00-5908271d5700
uuid:36c0345f-1dd2-11b2-0a00-bf0000000000
endstream
endobj
48 0 obj
<>
endobj
49 0 obj
<>
endobj
63 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
1 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
9 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
17 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
25 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
33 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
136 0 obj
[140 0 R]
endobj
137 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
12 789 587 -785 re
W n
q
0 792.06 612 -792 re
W n
BT
/CS0 cs 0 0 0 1 scn
/GS1 gs
/TT0 1 Tf
-0.00011 Tc 10 0 0 10 53.5 735.3264 Tm
(ACKNOWLEDGMENT)Tj
/TT1 1 Tf
0 Tc 0.0249 Tw 8 0 0 8 53.5 725.3264 Tm
[(W)79.8 (e)0.1 ( are grateful to Dr)54.9 (. Elizabeth Hensor for statistical advice.)]TJ
/TT0 1 Tf
-0.00011 Tc 0 Tw 10 0 0 10 53.5 701.3264 Tm
(REFERENCES)Tj
/TT1 1 Tf
0.02499 Tw 8 0 0 8 60.5 691.6264 Tm
[(1.)-875.1 (van der Heijde D, Calin )54.8 (A, Dougados M, Khan MA, van der)]TJ
0 Tc 1.675 -1.2125 Td
(Linden S, Bellamy N. Selection of instruments in the core set for)Tj
-0.00011 Tc 0 -1.2125 TD
[(DC-AR)59.7 (T)73.9 (, SMARD, physical therapy)64.8 (, and clinical record keeping in)]TJ
T*
[(ankylosing spondylitis. Progress report of the )54.8 (ASAS )17.7 (W)79.7 (orking)]TJ
0 Tc T*
[(Group. )54.8 (Assessments in )54.8 (Ankylosing Spondylitis. J Rheumatol)]TJ
0 Tw T*
(1999;26:951-4.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.2125 Td
[(2.)-875.1 (Pincus )17.7 (T)73.9 (,)-0.1 ( Sokka )17.7 (T)73.9 (. Quantitative measures for assessing rheumatoid)]TJ
0 Tc 1.675 -1.2125 Td
(arthritis in clinical trials and clinical care. Best Pract Res Clin)Tj
T*
(Rheumatol 2003;17:753-81.)Tj
-0.00011 Tc -1.675 -1.2125 Td
[(3.)-875.1 (Gladman DD, Helliwell PS, Mease PJ, Nash P)110.7 (,)-0.1 ( Ritchlin C, )17.7 (T)69.7 (aylor)]TJ
1.675 -1.2125 Td
[(W)91.7 (.)-0.1 ( )54.8 (Assessment of patients with psoriatic arthritis: a review of )]TJ
0 Tc T*
[(currently available measures. )54.9 (Arthritis Rheum 2004;50:24-35.)]TJ
-0.00011 Tc -1.675 -1.2125 Td
[(4.)-875.1 (Helliwell PS, Marchesoni )54.8 (A, Peters M, Barker M, )17.7 (W)39.7 (right )17.7 (V)129 (.)-0.1 ( )54.8 (A)]TJ
1.675 -1.2125 Td
(re-evaluation of the osteoarticular manifestations of psoriasis. Br )Tj
0 Tc T*
(J Rheumatol 1991;30:339-45.)Tj
-1.675 -1.2125 Td
[(5.)-875 (Gladman DD, Shuckett R, Russell ML, )17.7 (Thorne JC, Schachter RK.)]TJ
-0.00011 Tc 1.675 -1.2125 Td
(Psoriatic arthritis \(PSA\) \227 an analysis of 220 patients. QJM)Tj
0 Tc 0 Tw T*
(1987;238:127-41.)Tj
0.02499 Tw -1.675 -1.2125 Td
[(6.)-875 (Fournie B, Crognier L, )54.9 (Arnaud C, et al. Proposed classification )]TJ
1.675 -1.2125 Td
(criteria of psoriatic arthritis. Rev Rheum Engl Ed 1999;66:446-56.)Tj
-1.675 -1.25 Td
[(7.)-875 (Rothschild BM, Pingitore C, Eaton M. Dactylitis: implications for)]TJ
1.675 -1.25 Td
[(clinical practice. Semin )54.9 (Arthritis Rheum 1998;28:41-7.)]TJ
-1.675 -1.25 Td
[(8.)-875 (Olivieri I, Barozzi L, Favaro L, et al. Dactylitis in patients with)]TJ
1.675 -1.25 Td
[(seronegative spondylarthropathy)64.9 (. )54.8 (Assessment by ultrasonography)]TJ
0 -1.25 TD
[(and magnetic resonance imaging. )54.9 (Arthritis Rheum 1996;39:1524-8.)]TJ
31.325 34.9209 Td
[(9.)-875 (Kane D, Greaney )17.7 (T)74 (, Bresnihan B, Gibney R, FitzGerald O.)]TJ
1.675 -1.25 Td
(Ultrasonography in the diagnosis and management of psoriatic)Tj
T*
(dactylitis. J Rheumatol 1999;26:1746-51.)Tj
-2.175 -1.25 Td
[(10.)-875 (McGonagle D, Gibbon )17.7 (W)91.8 (,)0.1 ( Emery P)110.8 (. Classification of inflammatory)]TJ
2.175 -1.25 Td
[(arthritis by enthesitis. Lancet 1998;352:1)36.9 (137-40.)]TJ
-2.1381 -1.25 Td
[(1)36.9 (1.)-875 (Brockbank JE, Stein M, Schentag CT)74 (, Gladman DD. Dactylitis in)]TJ
-0.00011 Tc 2.1381 -1.25 Td
[(psoriatic arthritis: a marker for disease severity)64.8 (. )54.8 (Ann Rheum Dis)]TJ
0 Tc 0 Tw T*
(2005;64:188-90.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(12.)-875.1 (Anderson JJ, Felson DT)73.9 (, Meenan RF)79.7 (, )17.7 (W)39.7 (illiams HJ. )17.7 (Which )]TJ
0 Tc 2.175 -1.25 Td
(traditional measures should be used in rheumatoid arthritis clinical)Tj
T*
[(trials? )54.9 (Arthritis Rheum 1989;32:1093-9.)]TJ
-2.175 -1.25 Td
[(13.)-875 (Ritchie DM, Boyle JA, McInnes JM, et al. Clinical studies with an)]TJ
2.175 -1.25 Td
(articular index for the assessment of joint tenderness in patients)Tj
T*
(with rheumatoid arthritis. QJM 1968;37:393-406.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(14.)-875.1 (Kember P)110.7 (,)-0.1 ( )54.8 (Ainsworth L, Brightman P)110.7 (.)-0.1 ( )54.8 (A)-219.9 (hand anthropometric )]TJ
2.175 -1.25 Td
(survey of British workers. Cranfield, UK: Cranfield Institute of)Tj
0 Tc T*
[(T)69.8 (echnology; 1981.)]TJ
-2.175 -1.25 Td
[(15.)-875 (Fleiss JL. Measuring nominal scale agreement among many raters.)]TJ
2.175 -1.25 Td
(Psychol Bull 1971;76:378-82.)Tj
-2.175 -1.25 Td
[(16.)-875 (Gladman DD, Cook RJ, Schentag C, et al. )17.8 (The clinical assessment)]TJ
-0.00011 Tc 2.175 -1.25 Td
(of patients with psoriatic arthritis: results of a reliability study of)Tj
0 Tc T*
(the Spondyloarthritis Research Consortium of Canada. J Rheumatol)Tj
0 Tw T*
[(2004;31:1)36.9 (126-31.)]TJ
0.02499 Tw -2.175 -1.25 Td
[(17.)-875 (Clegg DO, Reda DJ, Mejias E, et al. Comparison of sulfasalazine)]TJ
2.175 -1.25 Td
[(and placebo in the treatment of psoriatic arthritis. )54.8 (A)-219.8 (Department of)]TJ
-0.00011 Tc T*
[(V)111 (eterans )54.8 (Af)17.7 (fairs Cooperative Study)64.8 (. )54.8 (Arthritis Rheum )]TJ
0 Tc 0 Tw T*
(1996;39:2013-20.)Tj
ET
/CS0 CS 0 0 0 1 SCN
53.46 77 m
558.47 77 l
S
0 0 0 0 scn
52.32 70.16 64.18 -15.66 re
f*
BT
0 0 0 1 scn
/TT2 1 Tf
8 0 0 8 53.3216 57.2343 Tm
(1750)Tj
ET
0 0 0 0 scn
355.5 70.16 203 -15.66 re
f*
BT
0 0 0 1 scn
/TT2 1 Tf
0.02499 Tw 8 0 0 8 423.8613 57.2343 Tm
(The Journal of Rheumatology 2005; 32:9)Tj
ET
0 0 0 0 scn
/GS0 gs
103.13 82.08 407.5 -10.83 re
f*
0.5 w
103.13 82.08 407.5 -10.83 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 g
/GS2 gs
/T1_0 8 Tf
108.828 74 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2005. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_1 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
101 0 obj
<>
endobj
119 0 obj
<>
endobj
36 0 obj
<>
endobj
69 0 obj
<>
endobj
65 0 obj
<>
endobj
67 0 obj
<>
endobj
93 0 obj
<>stream
HV PTW=A({tp
-fЈqE!RDCiQQ*e6u18qu*:e5FKJYq8JSjjqx.s} @TCAޘ2zN(@@Ňw %XZT9_?cam ZҊ^`9Յ@L0boYIx&+枾eTD
/(w-+sGo jīDQ*,̑ 3n_-P^qK@^W1{|˶tm[RՏ;I|DJ9 ,qdj)4ܨ{8XG7bF!w,qglG/>C,Ũd\?#8|u)zG_c)j`#U-ayVp#N1/'Z9XKD+hȧ;x#"d5ڣ7( *2;bY9>KWܟBY-`.u
+&hj[;$tAS05[όY˸" 1Deb8,NKQ+UźDVYfJ0'c